1502P CaboRISE (AIO-HEP-0320/ass.): A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with preserved liver function.
Saved in:
| Title: | 1502P CaboRISE (AIO-HEP-0320/ass.): A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with preserved liver function. |
|---|---|
| Authors: | Koch, C.1 (AUTHOR), Waldschmidt, D.T.2 (AUTHOR), Goetze, T.O.3 (AUTHOR), Ehmer, U.4 (AUTHOR), Ertl, S.5 (AUTHOR), Schmidt, H.6 (AUTHOR), Van Bömmel, F.7 (AUTHOR), Jacobasch, L.8 (AUTHOR), Pink, D.9 (AUTHOR), Wehler, T.C.10 (AUTHOR), Roderburg, C.11 (AUTHOR), Angermeier, S.12 (AUTHOR), Al-Batran, S-E.3 (AUTHOR), Brulin, T.13 (AUTHOR), Trojan, J.1 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS901-S901. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.2132 |
